Uscom

ASX RELEASE

# Supplementary Announcement
# Uscom Strategic Partnership with Foxconn China

**5 April 2022**

Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) is pleased to provide additional information to supplement the ASX announcement made yesterday regarding the agreement it has entered into with Foxconn.

The information, as required by ASX guidance note 8, is as follows:

1. Under the agreement, Foxconn will establish at their Beijing premises a manufacturing system to manufacture USCOM devices. The system will ensure the devices comply with NMPA and other regulatory requirements.
2. USCOM will pay a one-off fee for establishment of the system together with a fixed amount to produce a minimum number of units.
3. The agreement is significant to USCOM for the following reasons:
   (i) a marketing advantage by being able to sell China manufactured goods into the China market. This is a significant advantage over marketing foreign-made goods in China;
   (ii) the costs of manufacture charged by Foxconn, being the one-off fee and fixed amount to produce a minimum number of units, are less than the costs of manufacture currently incurred by USCOM in producing the devices; and
   (iii) by engaging with Foxconn, USCOM establishes an ongoing relationship with one of the world's leading high-tech manufacturing companies which is expected to result in the improvement of the devices and the development of new technology.
4. There are no conditions precedent to the agreement.

This announcement is authorised by Executive Chairman, Rob Phillips.

Uscom

ASX RELEASE

## About Uscom

**Uscom Limited (UCM)**: An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

**The USCOM 1A**: A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

**The Uscom BP+**: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

**Uscom SpiroSonic digital multi-path ultrasonic spirometers**: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, **SpiroReporter**, with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, occupational lung disease and monitoring of pulmonary therapeutic compliance.

**VENTITEST** digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.

For more information, please visit: www.uscom.com.au


## Uscom Contacts

Rob Phillips
Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary


This announcement is approved for release to the ASX by the Board of Uscom Limited.